Compare Costco Wholesale Corporation (COST) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Neurocrine Biosciences Inc — how do they compare? Costco Wholesale Corporation trades at $921.33 (market cap $408.78B), while Neurocrine Biosciences Inc trades at $171.02 (market cap $17.30B). The key difference: Costco Wholesale Corporation is far larger — about 23.6× Neurocrine Biosciences Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| COST | NBIX | |
|---|---|---|
Market Cap | $408.78B | $17.30B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $180.55 |
52-Week Low | $849.63 | $123.10 |
Enterprise Value | $396.92B | $16.39B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $920.54, down 0.64% on the day, with a bearish technical signal from moving averages. The company reported revenue of $275.24 billion in 2025, with net income of $8.10 billion, and recently announced strong March sales growth of 11.3% year-over-year (GlobeNewsWire, 2026-04-08). Analyst consensus is strongly bullish with a $1,120 price target, supported by 38 buy ratings.
The stock's high P/E of 46.37 reflects premium valuation, but consistent revenue growth and membership fee increases underpin fundamentals. Risks include competitive pressures and sensitivity to consumer spending. Upside potential exists if the stock pulls back toward support levels, aligning with analyst targets.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
